This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
It has been about a month since the last earnings report for Winnebago Industries, Inc. (WGO - Free Report) . Shares have lost about 8.6% in that time frame.
Winnebago is benefiting from strong tailwinds in the outdoor markets and a higher disposable income of its client base.
Wall Street doesn’t always get it right, but analysts’ track record is better than some skeptics suggest. And when the Street as a whole is arguing for big upside, investors should at least consider what those analysts have to say.
LRCX ARNC.PR HA TEVA ARNC.PRB AA.PRB MFIN GTN.A CMN AMAT HMNY CELG QUAD AA TRBAB MHO FOX SBNY AMC HXSCF AAL TMUS TRBNW VRX CMD ARNC MDT GTN MHK FOXA AMWD SBGI HXSCL MFINL OLED LEN MDCO TEVVF NFLX CXO WGO CHTR AAI RSPP AAPL DAL DIS LUV DISH SBNYW CMCSA THO NYTAB S XRAY TEVJF MU AA.PR DHI TRCO
U.S. customers have recently shown a distinct shift in the preference for trucks and sports utility vehicles (SUVs), shunning the traditional sedans. Automakers have already started to reorient their programs and strategies in response to the new situation, where the demand for conventional compact and midsize cars has declined while increased for SUVs and pickup trucks. The recent decision of General Motors Company (GM - Free Report) to abandon three Cadillac sedans and replacing them with two new ones over the next three and a half years vindicates this trend.
HINOF HYUO HOG WGO HYUD VLKAF HINOY MGA GM.WS.A 7205 GM.WS.B MG GM.WS.C GM HYUP GM.WSB AAP VLKAY
Winnebago Industries Inc. (WGO - Free Report) registered earnings of $1.02 per share in the third quarter of fiscal 2018 (ended May 28, 2018), beating the Zacks Consensus Estimate of 91 cents. In the year-ago period, earnings were 61 cents per share. Net income soared 67.7% to $32.5 million. Revenues in the reported quarter surged 18% to $562.3 million from $476.4 million in the prior-year quarter.
OSK ALSN WGO
Good day, ladies and gentlemen. And welcome to the Quarter Three Winnebago Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct the question-and-answer-session and instructions will follow at that time [Operator Instructions]. As a reminder, this conference call is being recorded.
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
NPSNY SYY RUTH LX MS DECK SRRK EQIX JACK MDT TACOW KNSA VZ ZOES FB CLPS QNST MCRI KR SMTC CCL RYDAF EVOP INTC DRRX ICLK MUSA ITUB BB UNFI RHT PTIE HLF JPM MU FNKO HBNC SBUX LOCO PLAY XOM TWX MS.PRE MS.PRF MS.PRG RDSB TOT RDSA MS.PRA SHAK HMNY SAFM BKS AAN OSTK GSKY INCY CTLR CCL BP MS.PRI GOOGL MS.PRK FLL RYDBF MKSI FITB CLR BB PPC BC NDLS DOGZ FND DRI SGBXQ FINL WGO COP XHR DAL ORCL DIS JASO F RDS.B RDS.A TACO DISH TMSR SPTN FDX VLO GOLF CHUY SNY CHEF W ITRM SGBX CVX SNE
The past week witnessed automakers releasing their U.S. auto sales report for May 2018. In May, vehicle sales in the United States increased by an estimated 2%. Low unemployment and robust consumer confidence reduced the impact of rising interest rates and fuel prices, and resulted in the rise in auto sales. Robust Memorial Day weekend sales also boosted retail auto deliveries. Automakers reported mixed US sales results for May.
COF.PRG COF.PRH NAV.PRD TM AZO COF.WS COF.PRP WGO COF-D COF-C COF-F GM.WS.A GM.WS.B GM.WS.C GM COF.PRC AAP FGP COF.PRD COF.PRF COF-P THO TYT COF HOG TOYOF NAV 7203 FCAU GM.WSB OXY
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to WGO / Winnebago Industries, Inc. on message board site Silicon Investor.
as of ET